Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Shilpa Medicare Business Update

Shilpa Biologicals has entered a co‑development and supply agreement with Finland's Orion for a nivolumab biosimilar. The partnership expands Shilpa's European market footprint.

Source

NSE filing, NSE: SHILPAMED. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Shilpa Medicare Ltd: key numbers

Share price
₹932.00
Market cap
₹18,228 Cr
Revenue (annual)
₹1,539 Cr
Net profit (annual)
₹243.3 Cr
P/E (TTM)
61.3×Sector 46.1×
Promoter holding
40.13%+0.00% QoQ
FII holding
12.11%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Shilpa Medicare Ltd

All →

Other business update announcements

All →